Cancer BiologybioRxivPreprint
Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance
S. Levesque, G. Carleton, V. Duque…·Y. Doyon
This study develops a CRISPR-based method to create rapamycin-resistant CAR-T cells, enabling pharmacological control of their activity in cancer therapy.
DOI 10.1101/2023.09.14.557485